Sequel Med Tech has announced that it has agreed to integrate its twiist automated insulin delivery system with Abbott‘s glucose-ketone sensor, which is currently under development.
Sequel said the agreement aims to improve outcomes for people with type 1 diabetes. It adds ketone sensing capabilities to a Libre glucose sensor in combination with twiist to enable the earlier detection of rising ketones. This marks an expansion on the existing integration of technologies between the two companies, as Sequel announced in March that it had agreed with Abbott to make the Libre system its first continuous glucose monitor (CGM) integration for twiist.
Twiist, combined with the twiist Loop algorithm, directly measures the volume of insulin delivered with every microdose. It offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system utilizes sound waves that measure each pulse of insulin. This enables precision and helps understand exactly how much insulin the patient receives in a dose.
To find out more, CLICK HERE.
